Advances in therapeutic cancer vaccines: Harnessing immune adjuvants for enhanced efficacy and future perspectives
Computational and Structural Biotechnology Journal · 2024-12 · 23 · 1833-1843
DOI: 10.1016/j.csbj.2024.04.054 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Computational and Structural Biotechnology Journal, online erschienen am 21.04.2024. Verfasst von Dekang Ren und 9 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Organic Electronics and Information Displays & Institute of Advanced Materials (IAM), Nanjing University of Posts and Telecom…. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 138 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Preventive cancer vaccines are highly effective in preventing viral infection-induced cancer, but advances in therapeutic cancer vaccines with a focus on eliminating cancer cells through immunotherapy are limited. To develop therapeutic cancer vaccines, the integration of optimal adjuvants is a potential strategy to enhance or complement existing therapeutic approaches. However, conventional adjuvants do not satisfy the criteria of clinical trials for therapeutic cancer vaccines. To improve the effects of adjuvants in therapeutic cancer vaccines, effective vaccination strategies must be formulated and novel adjuvants must be identified. This review offers an overview of the current advancements in therapeutic cancer vaccines and highlights in situ vaccination approaches that can be synergistically combined with other immunotherapies by harnessing the adjuvant effects. Additionally, the refinement of adjuvant systems using cutting-edge technologies and the elucidation of molecular mechanisms underlying immunogenic cell death to facilitate the development of innovative adjuvants have been discussed.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- State Key Laboratory of Organic Electronics and Information Displays & Institute of Advanced Materials (IAM), Nanjing University of Posts and Telecommunications, Nanjing 210023, China.
- Jiangsu Key Laboratory for Molecular and Medical Biotechnology, School of Life Science, Nanjing Normal University, Nanjing 210023, China.
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Ren, D., Xiong, S., Ren, Y., Yang, X., Zhao, X., Jin, J., Xu, M., Liang, T., Guo, L., & Weng, L. (2024). Advances in therapeutic cancer vaccines: Harnessing immune adjuvants for enhanced efficacy and future perspectives. Computational and Structural Biotechnology Journal, 23, 1833-1843. https://doi.org/10.1016/j.csbj.2024.04.054
Vancouver
Ren D, Xiong S, Ren Y, Yang X, Zhao X, Jin J, et al. Advances in therapeutic cancer vaccines: Harnessing immune adjuvants for enhanced efficacy and future perspectives. Computational and Structural Biotechnology Journal. 2024;23:1833-1843. doi:10.1016/j.csbj.2024.04.054
BibTeX
@article{Ren2024,
author = {Ren, Dekang and Xiong, Shizheng and Ren, Yujie and Yang, Xueni and Zhao, Xinmiao and Jin, Jiaming and Xu, Miaomiao and Liang, Tingming and Guo, Li and Weng, Lixing},
title = {Advances in therapeutic cancer vaccines: Harnessing immune adjuvants for enhanced efficacy and future perspectives},
journal = {Computational and Structural Biotechnology Journal},
year = {2024},
volume = {23},
pages = {1833--1843},
doi = {10.1016/j.csbj.2024.04.054}
}
EUVIMED